Clinical Study for the Effect of Low Carbohydrate Diet and Low Fat Diet on Non-alcoholic Fatty Liver Disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022975

Enrollment

Unknown

Registered

2019-05-05

Start date

2019-05-20

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liverdisease, NAFLD

Interventions

Low carb intervention group:Low Carb Diet

Low fat intervention group:Low Fat Diet

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Subjects or guardians voluntarily participate in the experiment and sign informed consent before entering the study; (2) 18-60 years of age, male and female (pregnant women); (3) The first diagnostic criteria must be nonalcoholic fatty liver; (4) When patients suffer from other diseases at the same time, but do not need special clinical treatment (no serious cardiovascular and cerebrovascular diseases, no serious digestive tract diseases, no serious liver and kidney function damage, no serious cognitive impairment, etc.), but also do not affect the implementation of the first diagnosis path process, can enter the path.

Exclusion criteria

Exclusion criteria: (1) Metabolic contraindications: carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine transferase II deficiency, beta-oxidase deficiency, medium chain acyl dehydrogenase deficiency, long chain acyl dehydrogenase deficiency, short chain acyl dehydrogenase deficiency, long chain 3-hydroxyacetyl coenzyme deficiency, medium chain 3-hydroxyacetyl coenzyme deficiency, pyruvate carboxylase deficiency Porphyria; (2) Complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat digestion disorder, severe cardiovascular and cerebrovascular diseases, etc.; (3) Special conditions taboos: pregnant, breast-feeding, infected, eating difficulties, can not cooperate with patients; (4) Drug contraindications: Antiepileptic drugs such as zonisamide, topiramate and acetazolamide can cause acidosis, which can be aggravated by ketogenic therapy.

Design outcomes

Primary

Measure	Time frame
liver function;renal function;TC/TG/HDL/LDL;Body composition determination;Liver B ultrasound;	—

Countries

China

Contacts

Public ContactQiao Yanxiang

Baoan Central Hospital of Shenzhen

18018719559@qq.com+86 18018719559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026